Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 130 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Cysteamine bitartrate (Procysbi) delayed release for Huntington’s Disease	Cysteamine bitartrate (Procysbi; RP103; Lynovex; NM001; Cystadrops; Mercaptamine)	Huntington's disease	Genetic Disorders , Neurology	2017	View \| Download
Dabigatran Etexilate (Pradaxa) for Secondary Stroke Prevention in Patients with Embolic Stroke of Undetermined Source – First Line	Dabigatran etexilate (Pradaxa)	Ischaemic stroke	Cardiovascular System	2017	View \| Download
Daratumumab (Darzalex) with lenalidomide and dexamethasone for multiple myeloma – first line	Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2017	View \| Download
Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes	Darbepoetin alfa (Aranesp)	Anaemia	Haematology	2017	View \| Download
Dasatinib (Sprycel) tablets for children with type II variation, philadelphia positive acute lymphoblastic leukaemia	Dasatinib (Sprycel; BMS 354825; dasatinib monohydrate)	Acute lymphoblastic leukaemia (ALL)	Haematological Cancer and Lymphomas	2017	View \| Download
Denosumab for the prevention of skeletal related events in patients with multiple myeloma – first line	Denosumab (AMG 162; Prolia; Xgeva)	Prevention of skeletal related events in multiple myeloma	Haematological Cancer and Lymphomas , Musculoskeletal System	2017	View \| Download
Domagrozumab (PF-6252616) for Duchenne muscular dystrophy in children and adolescents	Domagrozumab (PF-06252616)	Duchenne muscular dystrophy (DMD)	Genetic Disorders , Musculoskeletal System	2017	View
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2017	View \| Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Durvalumab in combination with Tremelimumab for locally advanced or metastatic urothelial bladder cancer – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2017	View \| Download